OncoPep is developing PVX-410, the first cancer vaccine designed to stop the progression of myeloma from the smoldering phase to active disease. PVX-410 is designed to be used in combination with agents that augment or modulates the patient’s immune response to the vaccine.
OncoPep is dedicated to developing transformative targeted immuno-therapeutics to prevent the progression of cancer, restore quality of life among patients and extend survival rates. Our goal is to halt the disease progression in smoldering multiple myeloma (SMM), multiple myeloma (MM) and triple negative breast cancer (TNBC).
We are assembling a pipeline of therapeutic cancer vaccines for mono and combination therapies to arm the immune system to attack cancer. Our lead program PVX-410 is currently positioned to enter Phase 2 clinical trials in smoldering multiple myeloma based on compelling proof-of-concept data measuring immune and clinical response.
PVX410 has the potential to be an important component in future combination immune-therapy regimens. OncoPep is currently advancing the development of PVX-410 for the treatment of patients with SMM and TNBC. Learn more about our ongoing trials and the therapeutic potential of PVX-410.